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A 48-Year-Old Man with Laryngeal Mass and Vocal Cord Palsy
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Figure 1. A, Histological examination of oropharyngeal biopsy specimen (May-Gru¨nwald Giemsa staining; original magnification, 1000) showing
intracellular amastigotes of Leishmania species (arrow). B, Laryngoscopic examination showing oropharyngeal area 3 months after completion of the
treatment.
Diagnosis: mucosal leishmaniasis.
Examination of biopsy specimens failed to identify tumoral
cells and revealed the presence of intracellular parasites that
were suggestive of Leishmania amastigotes (Figure 1A). Sero-
logical test results were positive for Leishmania species, with
a titer of 1:1280 ( ) in the blood. Results of quantita-n ! 1:80
tive, specific Leishmania polymerase chain reaction (PCR) per-
formed on the laryngeal lesion specimen were strongly positive,
with 400,000 parasites per million cells of tissue, but results
were negative when PCR was performed on plasma samples.
The patient was treated with a 28-day course of meglumine
antimoniate, which was administered at a dosage of 20 mg/kg
intravenously. Tolerance was excellent, and the patient’s dysp-
nea improved rapidly. The vocal cord palsy recovered com-
pletely after 6 weeks. Microlaryngoscopy at 3 months showed
a regression of the laryngeal lesions (Figure 1B).
Leishmaniasis is a parasitic disease that is prevalent world-
wide, is transmitted by the bite of infected female phleboto-
mus, and affects humans and some other vertebrates, such as
dogs and rats [1–5]. An estimated 12 million people are affected
worldwide, with 2 million new cases each year [4]. The inci-
dence of leishmaniasis has increased in settings with a high
prevalence of human immunodeficiency virus (HIV) infection.
Leishmaniasis is often considered to be an opportunistic in-
fection [6–9].
Leishmaniasis has diverse clinical presentations related to the
parasite species. Mucosal involvement of the nose, oral cavity,
pharynx, or larynx occurs in 2%–5% of persons infected with
Leishmania braziliensis. Generally, mucosal disease occurs 1
month to 2 decades after an initial cutaneous lesion.
Leishmaniasis presentations in patients who are co-infected
with HIV are more likely to involve atypical locations, dissem-
inated infection, and higher severity, especially among patients
with a CD4+ cell count !200 cells/mm3. In HIV-infected pa-
tients, leishmaniasis slows immune restoration and is associat-
ed with a high tendency to experience relapse [8–10]. Cases of
leishmaniasis mimicking malignant disorders or developing in
patients who have received a diagnosis of cancer have been
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described [11–15]. This can either lead to misdiagnosis or cause
a delay in the establishment of the correct diagnosis. Therefore,
leishmaniasis should be considered in the differential diagnosis
of malignancies in geographic areas in which it is endemic and
in patients with a history of travel to these areas.
Our patient was probably infected while living in Portugal
(where leishmaniasis is endemic) or during his annual trip
there. The patient’s high CD4+ cell count may explain the lack
of general signs of the disease. However, local tissue damage
as a result of radiotherapy could explain the spread and the
high local viral load of parasites. Few cases of leishmaniasis
after radiotherapy have been reported [14, 16].
There are several effective treatments for leishmaniasis. How-
ever, associated toxicities make them suboptimal. Pentavalent
antimonials are recommended as first-line treatment for most
patients, but they are associated with a high rate of primary
resistance [17]. There are no data that establish mucosal leish-
maniasis cure rates; however, there is evidence that pentavalent
antimony, pentamidine, and amphotericin B may be equally
effective [18]. Although current chemotherapy options result
in a clinical cure, they seldom lead to parasitologic cure. Re-
lapses usually occur within 6 months after treatment and are
common among HIV-infected patients. In addition to anti-
leishmanial chemotherapy, HIV-infected patients should re-
ceive antiretroviral therapy.
This case highlights the importance of histological diagnosis
of mucosal lesions in patients with a medical history of oro-
pharyngeal carcinoma. Histological confirmation of a suspect-
ed tumor resurgence should be standard practice.
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